NCT04359784View on ClinicalTrials.gov

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 27, 2021

Primary Completion Date

October 1, 2024

Study Completion Date

December 23, 2024

Conditions
B-Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Anakinra

Given IV (previously SC)

PROCEDURE

X-Ray Imaging

Undergo x-ray

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Computed Tomography

Undergo PET/CT or CT

PROCEDURE

Bone Marrow Aspiration

Undergo BMA

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Swedish Orphan Biovitrum
All Listed Sponsors
collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT04359784 - Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy | Biotech Hunter | Biotech Hunter